Lymphedema Risk No Higher With 3-Week RT Regimen in Early Breast Cancer
A 3-week hypofractionated RT course showed noninferiority to 5-week normofractionated RT in reducing lymphedema risk in early-stage breast cancer, with similar survival outcomes and no increased toxicity, according to the HypoG-01 trial. The study concludes that 3-week nodal RT should be the standard for breast cancer treatment.
Related Clinical Trials
Reference News
A 3-week hypofractionated RT course showed noninferiority to 5-week normofractionated RT in reducing lymphedema risk in early-stage breast cancer, with similar survival outcomes and no increased toxicity, according to the HypoG-01 trial. The study concludes that 3-week nodal RT should be the standard for breast cancer treatment.
HypoG-01 trial at 2024 ESMO Congress found moderately hypofractionated locoregional radiation therapy noninferior to standard normofractionated therapy in lymphedema risk for early breast cancer patients, with no detrimental effects on survival or shoulder range of motion. The study recommends 3-week regimens for nodal radiotherapy.